Page 32 - Read Online

Page 10 of 13 Li et al. Hepatoma Res 2020;6:15 I http://dx.doi.org/10.20517/2394-5079.2019.34

proliferation of CD4 T cells. Cell Mol Immunol 2019;17:178-89.
+
36. Hwang S, Han J, Baek JS, Tak E, Song GW, et al. Cytotoxicity of human hepatic intrasinusoidal CD56 bright natural killer cells against
hepatocellular carcinoma cells. Int J Mol Sci 2019;20:1564.
37. Easom NJW, Stegmann KA, Swadling L, Pallett LJ, Burton AR, et al. IL-15 overcomes hepatocellular carcinoma-induced NK cell
dysfunction. Front Immunol 2018;9:1009.
+
38. Sun H, Liu L, Huang Q, Liu H, Huang M, et al. Accumulation of tumor-infiltrating CD49a NK cells correlates with poor prognosis
for human hepatocellular carcinoma. Cancer Immunol Res 2019;7:1535-46.
39. Saparbay J, Tanaka Y, Tanimine N, Ohira M, Ohdan H. Everolimus enhances TRAIL-mediated anti-tumor activity of liver resident
natural killer cells in mice. Transpl Int 2020;33:229-43.
40. Gabrielson A, Wu Y, Wang H, Jiang J, Kallakury B, et al. Intratumoral CD3 and CD8 T-cell densities associated with relapse-free
survival in HCC. Cancer Immunol Res 2016;4:419-30.
41. Kalathil SG, Hutson A, Barbi J, Iyer R, Thanavala Y. Augmentation of IFN-gamma+ CD8+ T cell responses correlates with survival of
HCC patients on sorafenib therapy. JCI Insight 2019;4.
42. Zhou G, Sprengers D, Boor PPC, Doukas M, Schutz H, et al. Antibodies against immune checkpoint molecules restore functions of
tumor-infiltrating T cells in hepatocellular carcinomas. Gastroenterology 2017;153:1107-19.e10.
+
43. Wang X, He Q, Shen H, Lu XJ, Sun B. Genetic and phenotypic difference in CD8 T cell exhaustion between chronic hepatitis B
infection and hepatocellular carcinoma. J Med Genet 2019;56:18-21.
+
44. Kim HD, Park S, Jeong S, Lee YJ, Lee H, et al. 4-1BB delineates distinct activation status of exhausted tumor-infiltrating CD8 T cells
in hepatocellular carcinoma. Hepatology 2020;71:955-71.
+
45. Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, et al. Subsets of exhausted CD8 T cells differentially mediate tumor control and
respond to checkpoint blockade. Nat Immunol 2019;20:326-36.
+
+
+
46. Siddiqui I, Schaeuble K, Chennupati V, Fuertes Marraco SA, Calderon-Copete S, et al. Intratumoral Tcf1 PD-1 CD8 T cells with
stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 2019;50:195-
211.e10.
47. Yang YM, Kim SY, Seki E. Inflammation and liver cancer: molecular mechanisms and therapeutic targets. Semin Liver Dis
2019;39:26-42.
48. Lim CJ, Lee YH, Pan L, Lai L, Chua C, et al. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B
virus-related hepatocellular carcinoma. Gut 2019;68:916-27.
49. Yarchoan M, Xing D, Luan L, Xu H, Sharma RB, et al. Characterization of the immune microenvironment in hepatocellular carcinoma.
Clin Cancer Res 2017;23:7333-9.
+
+
+
50. Kalathil S, Lugade AA, Miller A, Iyer R, Thanavala Y. Higher frequencies of GARP CTLA-4 Foxp3 T regulatory cells and
myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res
2013;73:2435-44.
+
51. Yang L, Shao X, Jia S, Zhang Q, Jin Z. Interleukin-35 dampens CD8 T cells activity in patients with non-viral hepatitis-related
hepatocellular carcinoma. Front Immunol 2019;10:1032.
52. Huang XY, Ke AW, Shi GM, Zhang X, Zhang C, et al. alphaB-crystallin complexes with 14-3-3zeta to induce epithelial-mesenchymal
transition and resistance to sorafenib in hepatocellular carcinoma. Hepatology 2013;57:2235-47.
53. Wang X, Shen H, Zhangyuan G, Huang R, Zhang W, et al. 14-3-3zeta delivered by hepatocellular carcinoma-derived exosomes
impaired anti-tumor function of tumor-infiltrating T lymphocytes. Cell Death Dis 2018;9:159.
54. Aliahmad P, Seksenyan A, Kaye J. The many roles of TOX in the immune system. Curr Opin Immunol 2012;24:173-7.
55. Seo H, Chen J, González-Avalos E, Samaniego-Castruita D, Das A, et al. TOX and TOX2 transcription factors cooperate with NR4A
+
transcription factors to impose CD8 T cell exhaustion. Proc Natl Acad Sci U S A 2019;116:12410-5.
56. Scott AC, Dündar F, Zumbo P, Chandran SS, Klebanoff CA, et al. TOX is a critical regulator of tumour-specific T cell differentiation.
Nature 2019;571:270-4.
+
57. Wang X, He Q, Shen H, Xia A, Tian W, et al. TOX promotes the exhaustion of antitumor CD8 T cells by preventing PD1 degradation
in hepatocellular carcinoma. J Hepatol 2019;71:731-41.
58. Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, et al. Defining CD8 T cells that provide the proliferative burst after PD-1
+
therapy. Nature 2016;537:417-21.
59. Gehring AJ, Ho ZZ, Tan AT, Aung MO, Lee KH, et al. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-
related hepatocellular carcinoma. Gastroenterology 2009;137:682-90.
60. Hsu PN, Yang TC, Kao JT, Cheng KS, Lee YJ, et al. Increased PD-1 and decreased CD28 expression in chronic hepatitis B patients
with advanced hepatocellular carcinoma. Liver Int 2010;30:1379-86.
61. Xiao X, Lao XM, Chen MM, Liu RX, Wei Y, et al. PD-1hi Identifies a novel regulatory B-cell population in human hepatoma that
promotes disease progression. Cancer Discov 2016;6:546-59.
62. Lim TS, Chew V, Sieow JL, Goh S, Yeong JP, et al. PD-1 expression on dendritic cells suppresses CD8 T cell function and antitumor
+
immunity. Oncoimmunology 2016;5:e1085146.
63. Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and
postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009;15:971-9.
64. Jung HI, Jeong D, Ji S, Ahn TS, Bae SH, et al. Overexpression of PD-L1 and PD-L2 is associated with poor prognosis in patients with
hepatocellular carcinoma. Cancer Res Treat 2017;49:246-54.
+
65. Wu K, Kryczek I, Chen L, Zou W, Welling TH. Kupffer cell suppression of CD8 T cells in human hepatocellular carcinoma is
mediated by B7-H1/programmed death-1 interactions. Cancer Res 2009;69:8067-75.
66. Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, et al. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative